3-butyl-5-(cyclohexen-1-yl)-8-ethoxy-3-ethyl-2H-1,4-benzothiazepine

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 3-butyl-5-(cyclohexen-1-yl)-8-ethoxy-3-ethyl-2H-1,4-benzothiazepine
• 化学式: C₂₃H₃₃NOS
• 分子量: 371.6
• InChiKey: JMNNLSQJBOAKMO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.7
• 重原子数：
  26
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.61
• 拓扑面积：
  46.9
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• [EN] BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF BARRETT'S ESOPHAGUS AND GASTROESOPHAGEAL REFLUX DISEASE<br/>[FR] INHIBITEURS DE RECYCLAGE D'ACIDE BILIAIRE POUR LE TRAITEMENT DE L'ŒSOPHAGE DE BARRETT ET DU REFLUX GASTROŒSOPHAGIEN PATHOLOGIQUE
  申请人：LUMENA PHARMACEUTICALS INC

  公开号：WO2014144485A9

  公开（公告）日：2015-01-15
• BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF BARRETT'S ESOPHAGUS AND GASTROESOPHAGEAL REFLUX DISEASE
  申请人：Lumena Pharmaceuticals, Inc.

  公开号：EP2968262A1

  公开（公告）日：2016-01-20
• BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF PRIMARY SCLEROSING CHOLANGITIS AND INFLAMMATORY BOWEL DISEASE
  申请人：Lumena Pharmaceuticals, Inc.

  公开号：EP2968230A2

  公开（公告）日：2016-01-20
• GENOTYPE AND DOSE-DEPENDENT RESPONSE TO AN ASBTI IN PATIENTS WITH BILE SALT EXPORT PUMP DEFICIENCY
  申请人：Mirum Pharmaceuticals, Inc.

  公开号：EP3923943A1

  公开（公告）日：2021-12-22
• [EN] BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF PRIMARY SCLEROSING CHOLANGITIS AND INFLAMMATORY BOWEL DISEASE<br/>[FR] INHIBITEURS DU RECYCLAGE DE L'ACIDE BILIAIRE POUR LE TRAITEMENT DE L'ANGIOCHOLITE SCLÉROSANTE PRIMAIRE ET DE LA MALADIE INFLAMMATOIRE DE L'INTESTIN
  申请人：LUMENA PHARMACEUTICALS INC

  公开号：WO2014144650A2

  公开（公告）日：2014-09-18

  Provided herein are methods of treating or ameliorating primary sclerosing cholangitis and inflammatory bowel disease by administering to an individual in need thereof a therapeutically effective amount of an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTI) or a pharmaceutically acceptable salt thereof. Also provided are methods for treating or ameliorating primary sclerosing cholangitis comprising administering to an individual in need thereof a therapeutically effective amount of ASBTI or a pharmaceutically acceptable salt thereof.